New South Wales, with a population of 6.8 million, accounts for about one-third of the Australian population. School-based vaccination began in April 2007 for those aged 15 and older (enrolled female cohort about 114 000). In order to complete the course by the end of the school year in December, an accelerated vaccination schedule of 0, 1 and 4 months was used.
Identification and review of anaphylaxis episodes
Vaccines were administered by teams of nurses who provided a summary of doses administered and reported any adverse events following immunization daily by fax to the New South Wales Health Immunization unit. Notification of an adverse event, defined as an unwanted or unexpected event after the administration of vaccine, is mandatory under the New South Wales Public Health Act. Nationally, all such notifications are forwarded to the Adverse Drug Reactions Advisory Committee, a subcommittee of Australia's drug and therapeutics regulatory authority, the Therapeutic Goods Administration.
A panel of 13 people with a range of expertise (program delivery, pediatric allergy, surveillance of adverse events after vaccination and public health) was convened to review reports of adverse events following HPV vaccination. To determine the rates of anaphylaxis, we reviewed all reports of 1 or more of skin rash within 48 hours of immunization (n = 40), presumptive anaphylaxis (n = 8) or allergy (n = 28), and any cases where adrenaline had been administered (n = 9) or with respiratory or cardiovascular symptoms or both (n = 16).
Comparison with meningococcal vaccination program
A comparable expert panel had been previously convened to review reports of adverse events following a school-based meningococcal C vaccination program in 2003. This program, part of a national campaign to avert a further increase in cases of meningococcal C disease in Australia, administered 823 197 doses of vaccine to boys and girls aged [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] years. This panel classified relevant adverse events as anaphylaxis (n = 1), allergic reaction (n = 13) or rash (n = 10); there were 4 children who received adrenaline (New South Wales Health, unpublished data). We compared the rates of suspected anaphylaxis in this program to those in the HPV program, given similar surveillance systems and teams of school-based vaccinators. Similarly, in 1998 a national campaign to prevent a measles epidemic, with a large schoolbased component, delivered 1.7 million doses of measles-mumps-rubella vaccine to Australian children aged 5-12 years. An adverse events panel conducted an investigation into reports of allergic reactions.
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Clinical evaluation
Following an initial review, we contacted patients suspected to have had anaphylaxis, or their guardians, for written consent to conduct a telephone interview and to access their medical records (ambulance and hospital). Trained staff used a standardized, piloted questionnaire developed for this study for telephone interviews with the patient, the patient's guardian and the immunization provider who witnessed or managed the reaction. The patient and guardian questionnaire included demographic information, past medical history (especially of atopic disease and allergies), presenting symptoms, treatment and outcome, and immunization history. The provider questionnaire collected details of the preimmunization assessment of the patient, history of latex exposure, symptoms reported at the time of the event, clinical signs, treatment and overall clinical impression.
We invited all patients with suspected anaphylaxis to attend The Children's Hospital at Westmead for allergy testing at least 6 weeks after the episode. The allergy testing protocol included skin-prick testing for a panel of common antigens (cat, rye grass pollen, alternaria, house dust mite), vaccine components (baker's yeast [Saccharomyces cerevisiae], polysorbate 80) and the HPV vaccines Gardasil and Cervarix (GlaxoSmithKline). We performed intradermal testing (0.02 mL per injection) with HPV vaccines and polysorbate 80 (dilutions 1:100 and 1:10). The vaccine adjuvant (proprietary Merck amorphous aluminum hydroxyphosphate sulfate) was not available for inclusion in the protocol.
Following investigation, we classified cases using the Brighton case definition of anaphylaxis and the level of diagnostic certainty 2 (Box 1, Box 2). The Brighton definition refers to the level of diagnostic certainty but not the degree of severity of the case (i.e., a level 1 classification is associated with the greatest diagnostic certainty of anaphylaxis). For the purpose of applying the definition, we considered a rash that occurred at any site not contiguous with the injection site to be "generalized." We based our causality assessment on the timing of the onset of symptoms, according to the World Health Organization classification (i.e., certain/very likely, probable, possible, unlikely, unrelated), 4 and whether or not an alternative trigger was present.
Analysis
We calculated rates using the known number of administered doses from the school-based programs as the denominator and calculated exact Poisson 95% confidence intervals (CI). We also extracted published rates of anaphylaxis from other population-based vaccination programs and calculated 95% CIs.
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Results
In the 2007 school-based program, there were 269 680 doses of HPV vaccine administered. This consisted of dose 1 (n = 95 006, 83% coverage), dose 2 (n = 91 289, 80% coverage) and dose 3 (n = 83 845, 74% coverage). Of 155 adverse events reported after HPV vaccination, 110 were for vaccinations in the school program (41 per 100 000 doses). In the general practice program, there were 347 568 doses distributed, but the number of doses administered is not known. We initially classified 12 cases as requiring further investigation for suspected anaphylaxis. However, 1 patient did not provide consent for a telephone interview or medical record review, and thus was not further classified. Among the 12 cases, there was no geographic clustering or vaccine batch number implicated.
We reviewed all data for the 11 patients with suspected anaphylaxis, and we classified 8 (73%) as fulfilling the Brighton case definition (Table 1 ). Of these, 1 case was level 1, and 7 were level 2. Because the onset of symptoms occurred within 30 minutes of vaccination and because there was no alternate explanation, we determined that these cases were certain or very likely to have been caused by the vaccine. We considered and rejected the possibility that these cases could have been vasovagal episodes or somatic conversion disorder misdiagnosed as anaphylaxis. Of the 8 cases, 6 had generalized urticaria, 1 had angioedema and 1 had no dermatological signs but had stridor and hypoxia. Of the 3 cases not classified as anaphylaxis, 2 were classified as generalized allergic reactions on the basis of failure to progress, and 1 was considered unlikely to be a case of anaphylaxis because of the absence of objective signs and safe receipt of a subsequent dose. No alternate diagnosis could be suggested based on the available evidence. This person had been receiving high-dose steroids for Crohn disease at the time of the reaction.
Of the 8 confirmed cases, 7 were reported from the schoolbased program. The median age was 16.5 (min-max [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] years. Six cases were reported after dose 1 of the vaccine, and 
Based on the 7 confirmed cases of anaphylaxis from the school-based program (269 680 doses administered), the estimated rate of anaphylaxis following HPV vaccination was 2.6 per 100 000 doses administered (95% CI 1.0-5.3 per 100 000). Five cases occurred after dose 1 of the vaccine (95 006 doses administered), giving a rate of anaphylaxis of 5.3 per 100 000 people vaccinated (95% CI 1.7-12.3). Two cases occurred after the second dose (91 289 doses administered), giving a rate of anaphylaxis of 2.2 per 100 000 people vaccinated (95 % CI 0.3-7.9).
In comparison, the 2003 schoolbased meningococcal C vaccination program had 1 identified case of anaphylaxis (anaphylaxis rate 0.1 per 100 000 doses administered, 95% CI 0.003-0.7). A 13-year-old boy, who was coadministered the hepatitis B vaccine, immediately developed tachycardia, diaphoresis, chest pain, an itchy blocked throat, dysphagia, vomiting, agitation and a blotchy rash on his neck. He required 2 doses of adrenaline. On chart review performed for this study, 2 additional cases (girls aged 11 and 12 years) would have been assessed for suspected anaphylaxis in the current investigation, and they may have met the Brighton definition for anaphylaxis if full clinical information were available. One girl had complained of tongue swelling, throat tightness, and chest and abdominal pain 5 minutes after vaccination, and the other reported difficulty breathing and a rash on her neck and leg and at the injection site 1.5 hours after vaccination. If we include these cases, the anaphylaxis rate is 0.4 cases per 100 000 doses (95% CI 0.1-1.1).
Rates of anaphylaxis reported from other immunization programs are given in Table 2 and Appendix 1 (www.cmaj.ca /cgi/content/full/179/6/525/DC2).
Interpretation
The anaphylaxis rate in the 2007 school-based HPV vaccination program was 2.6 per 100 000 doses (95% CI 1.0-5.3 per 100 000 doses). This is higher than reported for other vaccines ( Table 2 ). The rate of anaphylaxis after HPV vaccination is comparable only to the rate following administration of vaccines containing bovine gelatin in Japan (Table 2) , which led to removal of the gelatin from the vaccine. 17 The lower limit of the confidence interval for the rate of anaphylaxis in the New South Wales HPV vaccination program overlaps with the upper limit of the confidence interval for the Canadian hepatitis B vaccination program and UK measles-rubella vaccination program (Table 2 ). Although the point estimate for the rate of anaphylaxis is higher than in previous programs, the estimated rate is still an order of magnitude less common than the World Health Organization categorization of adverse events after immunization which are "very rare" (< 1 in 10 000). 4 Unpublished safety data from the HPV vaccine manufacturer indicate that no vaccine safety signal for allergy or anaphylaxis was identified in the vaccine trials. 18 However, it is well recognized that prelicensure trials are underpowered to detect anaphylaxis.
2 Hypersensitivity reactions to HPV vaccine were the fifth most common adverse event reported to the Vaccine Adverse Events Reporting System in 2007, 19 and skin rash within 48 hours accounted for 26% of the reports of adverse events after HPV vaccination in New South Wales in 2007.
Reasons for the increased rate of anaphylaxis after HPV vaccine in the New South Wales school-based program are not clear but could be due to a number of factors including possible allergenicity of components of the HPV vaccine, enhanced passive adverse event surveillance and use of the Brighton definition of anaphylaxis. Another potential factor is that, from midadolescence onward, women have higher rates of anaphylaxis than men. 20, 21 An English study found that the risk of hospital admission for anaphylaxis is considerably higher among women of child-bearing age than in the rest of the population (rate ratio 1.38 95% CI 1.27-1.50). 21 The incidence of anaphylaxis in Australia also appears to be increasing. 20 A recent analysis by Siegrist and colleagues 22 anticipated the identification of vaccine safety signals for allergic and autoimmune diseases following population implementation of HPV vaccination because medical presentations for allergy-related conditions in young women are common. It is therefore important when assessing causality to note that all of our cases occurred within minutes of vaccination.
The school-based program in New South Wales might be expected to have high sensitivity for adverse events occurring soon after vaccination because experienced nursing teams provide both vaccine and postvaccination observation. However, the same arrangements were in place for the recent school-based vaccination program delivering meningococcal C vaccines to a similar age group in this region and no such signal was detected. Present definitions of anaphylaxis reflect the understanding that it has a variable spectrum of severity and presenting symptoms. This is an important issue when comparing rates with previous published reports, which are likely to be restricted to the most severe cases only. However, when we applied the definitions used in other recent studies of anaphylaxis following immunization to our cases, they all satisfied the case definition for probable anaphylaxis. 11, 13, 23 We found the Brighton classification useful, but we considered it inappropriate for screening because routine surveillance reports of adverse events following vaccination usually lack the necessary level of clinical detail.
Pre-existing allergen sensitization is biologically plausible for several components of the quadrivalent HPV vaccine. Natural HPV infection does not cause viremia; however, HPV virus-like particles are highly immunogenic when injected. 24 It is unclear whether some people may produce an IgE response to injected HPV antigens. One small trial injected participants (n = 30) with HPV type 11 virus-like particles and found no increase in IgE levels; 25 however, data from a study of rhesus macaques (n = 10) suggests it is possible. 26 Because the age group targeted by the HPV vaccination program was 15 years and older, many women may have already been exposed to HPV, because the median age of first sexual intercourse in Australia is 16 years. 27 There is potential for residual amounts of yeast proteins to be in the HPV vaccine. Although hypersensitivity to yeast is a documented phenomenon, 28 there have been infrequent reports of anaphylaxis or hypersensitivity reactions following the receipt of yeastcontaining vaccines. [29] [30] [31] [32] Quadrivalent HPV vaccine contains polysorbate 80 as a stabilizer. 33 Polysorbates are commonly used as solubilizers, stabilizers and emulsifiers in cosmetics and medical preparations. Polysorbate 80 could be a potential trigger of nonallergic ("anaphylactoid") anaphylaxis. There have been a number of reports of anaphylaxis or generalized hypersensitivity reactions occurring following the receipt of drugs that have implicated polysorbate 80 as the cause. [34] [35] [36] [37] Aluminum adjuvants are not a documented cause of anaphylaxis. 38 The most common event that may be confused with anaphylaxis during an acute episode is syncope. Syncope has also been reported following HPV vaccination, 19 but its onset is typically more rapid, with a person becoming unconscious in seconds. 39 The absence of urticaria, pruritus, angioedema or upper respiratory obstruction are helpful in differentiating syncope from anaphylaxis, as are the presence of pallor instead of flushing and nausea without abdominal pain. 40 All of the people with anaphylaxis in the New South Wales HPV vaccination program recovered completely. Most did so rapidly after administration of adrenaline and were asymptomatic by the time they reached the emergency department (20-60 minutes later). In such cases, primary care staff may need to rely on witness and patient history to obtain a complete clinical picture.
In July 2007, the package insert for the quadrivalent HPV vaccine was updated to reflect reports of anaphylaxis following HPV vaccination, and the product information has been updated internationally by the manufacturer. Following confirmation of the vaccine safety signal, all general practitioners in New South Wales were reminded via fax to be prepared for the occurrence of anaphylaxis following HPV vaccination and to have appropriate protocols and equipment available. Consent forms used in the schoolbased program include the small but real risk of anaphylactic reaction. In December 2007, the Therapeutic Goods Administration placed advice on its website alerting providers to the occurrence of anaphylaxis following HPV vaccination. 41 In 
Limitations
This study had several limitations. First, because expert bodies find it difficult to define anaphylaxis, the classification of a case as anaphylaxis will be somewhat imprecise and dependent on the particular definition used. The available details are those recorded by the immunization nurses and are not as complete as those documented in a clinical trial setting. Full clinical details were not available for all cases. Second, there was a delay of weeks to months between the event and the interview, because of delays in reporting, obtaining consent and availability of cases for interview. Third, the small number of cases identified in this and other reports of anaphylaxis following vaccination makes estimates of incidence imprecise and comparison between case series vulnerable to misclassification. This makes the true magnitude of the difference between the incidence identified here and that for other vaccines uncertain, with misclassification of only 1 or 2 cases capable of substantially altering estimates of fold differences. This is especially true when differences in the propensity for the occurrence and recognition of possible anaphylaxis by age group and sex are taken into account. 2, [20] [21] [22] Nevertheless, we attempted to be exhaustive in our evaluation of the cases, and the case identification pathways were identical to those in recent comparable school-based campaigns. School-based HPV vaccination campaigns are being conducted in Canada, the United Kingdom and elsewhere, so awareness of this experience should focus attention on the Research identification of anaphylaxis and lesser possible allergic manifestations, such as urticarial rash, in order to enlarge the available denominator
Conclusion
Anaphylaxis following HPV vaccination is a rare event, as defined by the World Health Organization, 4 and it should not curtail population-based HPV vaccination programs. It is noteworthy that no cases of anaphylactic shock occurred, but it is important to note the wide clinical spectrum of anaphylaxis. 2 Although this makes confirming that these cases truly represent anaphylaxis difficult, it also highlights the importance of good training for staff administering vaccines in school or other settings in the recognition and management of suspected anaphylaxis and its reporting. Routine reporting forms for adverse events following vaccination could include prompts to ensure that enough detail is recorded to allow subsequent classification using the Brighton definition of anaphylaxis. The biological basis for the reported reactions to HPV vaccine requires further research.
